Related Experiment Video
Updated: Apr 21, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Clopidogrel: A multifaceted affair
Efrén Martínez-Quintana1, Antonio Tugores
1Cardiology Department, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain.
Insights
Patient response to clopidogrel, an antiplatelet medication, varies. Current genetic tests and platelet reactivity assays are not reliable predictors of clopidogrel resistance in patients at risk for vascular events.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Genetics
Background:
- Clopidogrel, combined with aspirin, is a standard antiplatelet therapy for preventing vascular thrombotic events.
- Individual patient responses to clopidogrel vary, necessitating methods to predict therapeutic resistance.
- The pharmacokinetics of clopidogrel are complex, influenced by cytochromes, target tissue, and clinical factors.
Purpose of the Study:
- To evaluate the clinical utility of predicting clopidogrel resistance.
- To assess the role of CYP2C19 genotyping in clopidogrel response.
- To determine if ex vivo platelet reactivity assays can guide antiplatelet therapy.
Main Methods:
- Review of evidence regarding clopidogrel pharmacokinetics and pharmacodynamics.
- Analysis of studies on CYP2C19 genetic variations and drug interactions.
- Evaluation of the robustness and clinical applicability of platelet reactivity assays.
Main Results:
- No robust evidence links CYP2C19 function (alleles or inhibitors) to clinical response to clopidogrel.
- Ex vivo platelet reactivity assays lack the robustness for tailoring anti-aggregation treatment.
- Certain clinical conditions (diabetes, obesity, CAD, stenting) are associated with higher cardiovascular event risk.
Conclusions:
- CYP2C19 genotyping is not a reliable predictor of clopidogrel response.
- Tailoring antiplatelet therapy based on platelet reactivity assays is currently not feasible.
- Identifying high-risk clinical conditions is a prudent strategy for optimizing antiplatelet therapy, potentially using more potent agents with patient counseling.
Abstract:
Clopidogrel has been the therapy of choice, combined with aspirin, against platelet aggregation in patients at risk of suffering a vascular thrombotic event. Not all patients respond equally to clopidogrel, an observation that has led to searching for a test that, in the clinical setting, could predict patients' "resistance" to therapy. The evidence reveals a complex pharmacokinetic profile for clopidogrel, with multiple players involved, including cytochromes, characteristics of the target tissue, and accompanying clinical conditions. Despite FDA black box warnings recommending CYP2C19 genotyping before clopidogrel use, no robust evidence indicates that CYP2C19 function determines clinical response to the drug, either based on the presence of loss of function alleles or drug interactions with CYP2C19 inhibitors, like omeprazole. A tailored anti-aggregation treatment based on ex vivo platelet reactivity also seems unlikely due to the lack of robustness of most assays. The identification of clinical conditions that are at higher risk of new cardiovascular events, such as diabetes, obesity, coronary artery disease, or specific stenting procedures, seems to be a prudent approach to tailor anti-platelet therapy with more powerful drugs, accompanied by careful counseling to promote patient compliance.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:27Coronary Artery Disease V: Interprofessional Care
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins